The earnings call highlighted significant achievements, including record-breaking ORLADEYO performance, strong financial management, and strategic advancements in the pipeline. The successful sale of the European business and leadership transition further strengthened the company's position. While there are potential challenges with new market entrants and a delay in the pediatric ORLADEYO approval, the positive aspects of the call significantly outweigh the lowlights.

Company Guidance

In the recent BioCryst Second Quarter 2025 Earnings Conference Call, the company reported impressive metrics, particularly for ORLADEYO, which achieved its best quarter since approval. ORLADEYO's revenue for Q2 was $156.8 million, representing a 45% increase year-over-year, with $140.3 million generated in the U.S. The company anticipates reaching the upper half of its revenue guidance of $580 million to $600 million for the full year, despite removing European revenue in Q4 due to the sale of its European business. The commercial performance was bolstered by a 10% increase in new patient prescriptions from Q1 2021 and a 15% rise from Q1 this year. BioCryst's non-GAAP operating expenses were $106.4 million, up from $87.4 million in Q2 2024, while non-GAAP operating profit was $57 million. The company generated $45 million in cash before debt prepayment and paid down $125 million in principal from its term loan, reducing the balance to $199 million. BioCryst is on track to generate $700 million in cash by 2027 and plans to use this financial strength to explore opportunities for growth through acquisitions and pipeline expansion.

Record ORLADEYO Performance

The second quarter of 2025 was the best ever for ORLADEYO, with new patient prescriptions up over 10% above the first quarter of the launch in 2021 and over 15% above Q1 this year. ORLADEYO revenue exceeded expectations by more than $22 million above Q1 and showed a 45% growth year-over-year.

Strong Financial Position

Total revenue for the quarter was $163.4 million, with ORLADEYO accounting for $156.8 million. The company generated $45 million of cash in the second quarter before any debt prepayment and paid down $75 million in principal from its term loan in April and an additional $50 million in July.

European Business Sale

BioCryst signed a definitive agreement to sell its European business to Neopharmed Gentili, expected to close in early October. This deal will enable the company to pay off its term debt and improve its operating profit margin.

Pipeline Progress

The Netherton syndrome and DME pipeline programs remain on track to have data by the end of the year. The company anticipates FDA approval of ORLADEYO granules in December.

Successful Leadership Transition

Charlie Gayer was chosen as the next CEO, following a successful succession planning process. Jon Stonehouse will work with Charlie for a smooth transition into the new year.

BioCryst (BCRX) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

BCRX Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Oct 29, 2025	2025 (Q3)	0.03 / -	-0.07	―	―	―
Aug 04, 2025	2025 (Q2)	<0.01 / 0.02	-0.06	133.33% (+0.08)
May 05, 2025	2025 (Q1)	-0.08 / 0.00	-0.17	―
Feb 24, 2025	2024 (Q4)	-0.05 / -0.13	-0.31	58.06% (+0.18)
Nov 04, 2024	2024 (Q3)	-0.07 / -0.07	-0.19	63.16% (+0.12)
Aug 05, 2024	2024 (Q2)	-0.17 / -0.06	-0.4	85.00% (+0.34)
May 06, 2024	2024 (Q1)	-0.21 / -0.17	-0.28	39.29% (+0.11)
Feb 26, 2024	2023 (Q4)	-0.25 / -0.31	-0.38	18.42% (+0.07)
Nov 02, 2023	2023 (Q3)	-0.24 / -0.19	-0.23	17.39% (+0.04)
Aug 03, 2023	2023 (Q2)	-0.23 / -0.40	-0.32	-25.00% (-0.08)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

BCRX Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 04, 2025	$7.95	$8.73	+9.81%
May 05, 2025	$8.93	$11.03	+23.52%
Feb 24, 2025	$9.21	$8.29	-9.99%
Nov 04, 2024	$8.43	$7.35	-12.81%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.